The role of ventriculoperitoneal shunting in patients with supratentorial glioma
Article first published online: 10 DEC 2013
© 2013 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Annals of Clinical and Translational Neurology
Volume 1, Issue 1, pages 45–48, January 2014
How to Cite
de la Fuente, M. I. and DeAngelis, L. M. (2014), The role of ventriculoperitoneal shunting in patients with supratentorial glioma. Annals of Clinical and Translational Neurology, 1: 45–48. doi: 10.1002/acn3.17
- Issue published online: 22 JAN 2014
- Article first published online: 10 DEC 2013
- Manuscript Revised: 26 SEP 2013
- Manuscript Accepted: 26 SEP 2013
- Manuscript Received: 16 AUG 2013
To assess the impact of ventriculoperitoneal (VPS) in patients with glioma.
Retrospective review of patients with grade II-IV glioma who had VPS placement from January 1995 to November 2012.
We identified 62 patients. At time of VPS, 41 had gait disturbance, 40 cognitive impairment and 16 urinary incontinence; 10 had the classic triad. Thirty-eight (61%) improved after VPS. Median overall survival from VPS was 7 months for all patients, but 11 months for those who improved and 2 months for non-responders. Leptomeningeal disease, glioma grade or radiographic ventricular decompression did not predict benefit.
VPS can improve functional status in some patients with symptoms suggestive of hydrocephalus.